Focus: Magnolia Medical Technologies is a Seattle-based biotechnology company of 5,000+ employees specializing in sepsis diagnosis devices, particularly the Steripath blood culture contamination prevention system. The company operates in the infectious disease diagnostic space with a focus on improving clinical laboratory workflows.
Profile data last refreshed 5h ago · AI intelligence enriched 2w ago
Cooling — net -5 jobs in 30d
0 added, 5 removed. Slower than typical.
Best suited for commercial, sales, and supply-chain professionals seeking stability in a established mid-cap diagnostics company; R&D and strategic careers should verify pipeline depth and litigation exposure before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Magnolia Medical Technologies
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Magnolia Medical Technologies's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Magnolia Injunction Bid Fails After Verdict Win Against Kurin - Bloomberg Law News
Magnolia Injunction Bid Fails After Verdict Win Against Kurin Bloomberg Law News
USPTO director steps into Sun Pharma’s PTAB-ITC clash - Life Sciences IP Review
USPTO director steps into Sun Pharma’s PTAB-ITC clash Life Sciences IP Review
Magnolia Medical Technologies Lobbyists, 2026 - OpenSecrets
Magnolia Medical Technologies Lobbyists, 2026 OpenSecrets
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo